Skip to main content

Articles

ASCO 2017 - Chronic Lymphocytic Leukemia

Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study

ASCO 2017 - Chronic Lymphocytic Leukemia

A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas

ASCO 2017 - Chronic Lymphocytic Leukemia

Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)

ASCO 2017 - Chronic Lymphocytic Leukemia

Tolerability and Activity of the Chemotherapy-Free Triplet TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL

ASCO 2017 - Chronic Lymphocytic Leukemia

Randomized, Double-Blind Phase 3 Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New-Onset cGVHD

ASCO 2017 - Chronic Lymphocytic Leukemia

Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL

ASCO 2017 - Chronic Lymphocytic Leukemia

COSMOS: A 2-Cohort, Phase 2 Study of MOR208 plus Idelalisib or Venetoclax in Patients with R/R CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study

Page 88 of 244
Results 871 - 880 of 2434